Drug Trial Radar · NCT06344533
Study of JMKX003142 Injection in Chinese Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
78
Planned (sponsor's estimate)
Start
Apr 10, 2024
Primary completion
Jan 31, 2025
Study completion May 30, 2025
Sponsor
- Lead sponsor
- JemincareIndustry
- Sponsor type
- Industry
- Collaborators
- Zhejiang Hangyu Pharmaceutical Co., Ltd.
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142 Injection Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Doses in Chinese Healthy Adult Subjects
Conditions
- Healthy Adult
Interventions
JMKX003142 InjectionDrug
JMKX003142 Injection will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
PlaceboDrug
Matching placebo will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of the Adverse Events that are related to the single dose treatmentTime frame: From Baseline to Day7
- Number of the Adverse Events that are related to the multiple dose treatmentTime frame: From Baseline to Day12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.